We wish to inform you that the Board of Directors of Asarfi Hospital Limited ('the Company'), at its meeting held today, i.e., November 10, 2025, has considered and approved the Unaudited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.2 pts more than Nifty Microcap 250 and 9.6 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Asarfi Hospital Limited, at its meeting on November 10, 2025, approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025. The statutory auditors, M/s R. K. Thakkar & Co, Chartered Accountants, carried out a limited review and issued an unmodified (clean) opinion on both sets of results. Separately, the company disclosed it has availed a ₹4.68 crore term loan from State Bank of India to purchase and install a new Cath Lab at its Dhanbad hospital, along with a ₹2.00 crore fund-based Bank Guarantee limit to support empanelments with corporates and PSUs.
A clean audit opinion is reassuring for shareholders, while the Cath Lab acquisition signals capacity expansion and the SBI-backed funding strengthens banking ties. Investors should review the detailed financial results for actual revenue and profitability trends.